Open GLP‑1 Price Index: list price vs cash price
US list price (WAC) and cash price for every semaglutide, tirzepatide and orforglipron product, with sources, check dates and method. Free CSV under CC BY 4.0.
About this data set
Key findings
- 1.
The Wegovy pen cash price of $349 a month is 74% below its list price (WAC) of $1,349.02 per package, a gap of $1,000.02. As of October 25, 2026.
Source: novocare.com (Wegovy)
- 2.
The Zepbound cash price of $299–449 a month (midpoint $374) is 66% below its list price (WAC) of $1,086.37 per package, a gap of $712.37. As of October 25, 2026.
Source: LillyDirect (Zepbound)
- 3.
The Ozempic pen cash price of $349–499 a month (midpoint $424) is 59% below its list price (WAC) of $1,027.51 per package, a gap of $603.51. As of October 25, 2026.
Source: novocare.com (Ozempic)
- 4.
The Mounjaro pen cash price of $499 a month is 55% below its list price (WAC) of $1,112.16 per package, a gap of $613.16. As of October 25, 2026.
Source: LillyDirect (Mounjaro)
- 5.
The Foundayo tablets cash price of $149–299 a month (midpoint $224) is 65% below its list price (WAC) of $649 per package, a gap of $425. As of October 25, 2026.
Source: LillyDirect (Foundayo)
- 6.
The lowest verified compounded semaglutide price of $49 a month is 96% below the Wegovy list price (WAC) of $1,349.02 per package, a gap of $1,300.02. As of October 25, 2026.
Source: WellMedr review
- 7.
The lowest brand-name cash price in the index is Wegovy tablets, at $149–299 a month ($149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg). Rybelsus tablets and Zepbound single-dose pen have no cash price: being replaced by the Ozempic pill; the savings card requires commercial coverage; sold through insurance; the savings card requires commercial coverage.
Source: novocare.com (Wegovy)
The index
One row per product. The list price is per package. The cash price is per month. Each price names the page it was read from and the day.
¹ Wholesale acquisition cost: the maker’s published price to wholesalers, before discounts and rebates. ² As the program states it. A range is a dose-tiered price; “from” is the lowest entry price. ³ Compounded products have no maker and no WAC.
List price against cash price
The percentage is (list − cash) ÷ list, rounded to the nearest whole number. Where the cash price is tiered by dose, we use the midpoint of the tiers.
Monthly editions
The index as it stood on the first day of each month. An edition is never changed after it is published; a correction goes in the next one.
Methodology
Definitions
List price (WAC). Wholesale acquisition cost: the price the maker publishes to wholesalers, per package, before discounts and rebates. It is not what a pharmacy pays, not what an insurer pays after rebates, and not a cash price.
Cash price. What a person with no insurance pays for one month through the maker’s own channel, as the program states it on its page.
Compounded price. The lowest verified monthly price, medication included, across the compounded programs in our program register. It counts any membership the program bills on top, the same total our rankings use. Compounded drugs are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold.
Sources
- Novo Nordisk self-pay and list-price pages: Wegovy, Wegovy list price, Ozempic, Ozempic list price and Rybelsus.
- Eli Lilly self-pay pages: Zepbound, Mounjaro and Foundayo, and Lilly’s list-price pages for Zepbound, Mounjaro and Foundayo.
- Our program register, for compounded prices. Each compounded row links to the review of the program that sets the lowest price, where its plans and the day we last confirmed them are listed.
- CMS NADAC (National Average Drug Acquisition Cost): the price pharmacies pay, per NDC. Not yet in the index. See limitations.
Inclusion rules
The index includes every brand-name semaglutide, tirzepatide and orforglipron product sold in the United States: Wegovy (pen and tablets), Ozempic (pen and pill), Rybelsus, Zepbound (vials, KwikPen and single-dose pen), Mounjaro and Foundayo. It includes compounded semaglutide and compounded tirzepatide as one row each. A price goes in only when we can read it on a public page or in a program’s verified prices. Where a maker does not publish a WAC or a cash price, the cell says so. We do not estimate a missing price.
Update cadence
Every week we re-read each maker price from the page the row cites. When the page still shows the same price, the row’s check date moves to that day. When it shows a different one, a person checks it before the row changes. Compounded prices update with our program register, which re-checks each program’s prices against its own site. On the first day of each month the index is frozen as a dated edition. The newest check of a maker price was October 25, 2026. The newest check of a compounded price was October 26, 2026.
Limitations
- Units differ by column. WAC is per package (28 days for pens and vials, 30 tablets for tablets). Cash is per month. Compare the two only for products where one package is one month.
- Many cash prices are tiered by dose. A range gives the lowest and highest tier. The spread table uses the midpoint.
- Some cash prices have conditions: new-patient prices, refill windows, dose tiers. The note column states them.
- Compounded prices are entry prices. The price at higher doses is usually higher, and it changes from program to program. The lowest price is often on a plan billed for several months at once; the note column says so.
- The index does not include insurance copays, net prices after rebates, or Medicare and Medicaid prices. For those, use the cost calculator.
- The index does not include NADAC yet. NADAC is the next column we plan to add.
- Prices change. Every figure is true on its check date only.